Literature DB >> 8559046

Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia.

R L Peper1, H Van Campen.   

Abstract

The role of tumor necrosis factor alpha (TNF alpha) in the pathogenesis of influenza A viral pneumonia was examined. CD-1 male mice were challenged intranasally with influenza A virus A/PR/8/34 (H1N1) and administered rabbit anti-mouse TNF alpha-specific-neutralizing antibodies intraperitoneally. The effect of treatment on virus titer, TNF alpha levels, morbidity, mortality, and on pathologic lung lesions were compared with sham-treated controls. The severity of gross and histologic lung lesions positively correlated with the peak bronchoalveolar TNF alpha levels and was ameliorated with anti-TNF alpha treatment. Survivorship was prolonged in mice given a lethal dose of virus by treatment with TNF-alpha neutralizing antibodies. Reduction of TNF alpha levels by treatment with TNF alpha-antibodies did not affect virus titers in the lung. These results suggest that TNF alpha is a mediator of pulmonary inflammation during influenza A viral pneumonia, but may not play a significant anti-viral role in influenza pneumonia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8559046     DOI: 10.1006/mpat.1995.0056

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  46 in total

1.  Mapping the pulmonary environment of animals protected from virulent H1N1 influenza infection using the TLR-2 agonist Pam₂Cys.

Authors:  Edin J Mifsud; Amabel C L Tan; Patrick C Reading; David C Jackson
Journal:  Immunol Cell Biol       Date:  2015-08-14       Impact factor: 5.126

2.  CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection.

Authors:  Kaifeng Lisa Lin; Shari Sweeney; Brian Donghoon Kang; Elizabeth Ramsburg; Michael Dee Gunn
Journal:  J Immunol       Date:  2010-11-22       Impact factor: 5.422

Review 3.  Tipping the balance in favor of protective immunity during influenza virus infection.

Authors:  Eric G Pamer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-25       Impact factor: 11.205

4.  Mutations in influenza virus M1 CCHH, the putative zinc finger motif, cause attenuation in mice and protect mice against lethal influenza virus infection.

Authors:  Eric Ka-Wai Hui; Donald F Smee; Min-Hui Wong; Debi P Nayak
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 5.  Influenza, immune system, and pregnancy.

Authors:  Renju S Raj; Elizabeth A Bonney; Mark Phillippe
Journal:  Reprod Sci       Date:  2014-06-04       Impact factor: 3.060

6.  Effects of tumor necrosis factor on viral replication and pulmonary inflammation during acute mouse adenovirus type 1 respiratory infection.

Authors:  Krittika Pant; Adithya Chandrasekaran; Christine J Chang; Aditya Vageesh; Alexandra J Popkov; Jason B Weinberg
Journal:  Virology       Date:  2020-05-23       Impact factor: 3.616

7.  Direct IL-6 Signals Maximize Protective Secondary CD4 T Cell Responses against Influenza.

Authors:  Tara M Strutt; Karl Kai McKinstry; Yi Kuang; Caroline M Finn; Ji Hae Hwang; Kunal Dhume; Stewart Sell; Susan L Swain
Journal:  J Immunol       Date:  2016-09-19       Impact factor: 5.422

8.  Anti-TNF-alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs.

Authors:  Kalina Atanasova; Steven Van Gucht; Kristien Van Reeth
Journal:  Vet Immunol Immunopathol       Date:  2010-04-13       Impact factor: 2.046

Review 9.  The effector T cell response to influenza infection.

Authors:  Matthew M Hufford; Taeg S Kim; Jie Sun; Thomas J Braciale
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

10.  Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza.

Authors:  Lisa M Alleva; Charles Cai; Ian A Clark
Journal:  Evid Based Complement Alternat Med       Date:  2009-09-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.